L’uso clinico degli antidepressivi noradrenergici

Aguglia E., Anzallo C., Ballatore A.

Istituto di Clinica Psichiatrica - Università di Trieste

INTRODUZIONE

GLI ANTIDEPRESSIVI NORADRENERGICI NON SELETTIVI

GLI INIBITORI SELETTIVI DELLA RICAPTAZIONE DELLA NORADRENALINA (NRI)

CONCLUSIONI

BIBLIOGRAFIA

Bibliografia

Altamura A.C., Mannu P. (1998a). Venlafaxina in social phobia: a study in SSRIs non responders. Giorn. It. Di Psicopatologia, 4: 65-66 suppl.

Altamura AC, Mannu P. (1998b). Ipotesi neurochimiche dei disturbi depressivi e razionalizzazione del trattamento farmacologico. Quaderni italiani di Psichiatria, 5:281-319.

Ban T.A., Gaszner P., Aguglia E. et al. (1998). Clinical efficacy of reboxetine: a comparative study with desimipramine, with methodological considerations. Human Psychopharmacology, vol 13 S29- S39

Berzewski H., Van Moffaert M., Gagiano CA. (1997). Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes. European Neuropsychopharmacology. 7 Suppl 1:S37-47

Brunello N., Racagni G. (1998). Rationale for development of noradrenaline reuptake inhibitors. Human Psychopharmacology 13 (suppl. 1), 513-519

Geracioti TD Jr. (1995). Venlafaxine treatment of panic disorder: a case series. Journal of Clinical Psychiatry. 56(9):408-10

Kasper S. (1995). Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. International Clinical Psychopharmacology, 10 suppl. 4, 25-35

Mendlewicz J. (1995). Pharmacologic profile and efficacy of venlafaxine. International Clinical Psychopharmacology. 10 Suppl 2:5-13

Montgomery S.A. (1995). Safety of Mirtazapine: a review. International Clinical Psychopharmacology, 10 suppl. 4, 37-45

Nemeroff C. B., De Vane C. L., Pollok B. G. (1996). Newer antidepressant and the cytochrome P450 system. American Journal of Psychiatry 153, 311-320

Rauch S.L., O’Sullivan R.L., Jenike M.A. et al. (1996). Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J. Clin. Psychopharmacology, 16:82-84

Sacchetti E. (1998). Reboxetina aspetti clinici e terapeutici. Giornale Italiano di Psicopatologia, vol 4:16-18 suppl.

Schweizer E. Feighner J. Mandos LA. Rickels K, (1994). Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. Journal of Clinical Psychiatry. 55(3):104-8.

Shrivastava R.K., Cohn C., Crowder J, et al. (1994). Long-term safety and clinical acceptability of venlafaxine and imipramine in outpatient with major depression. Journal Clin. Psychopharmacol, 14: 322-329

Szapiro N. (1995). The significance of viloxazine in the treatment of major depressed patient. C-R-Ther-Pharmacol-Clin, 13/126 (18-22)

Tignol J. Pujol-Domenech J. Chartres JP. Leger JM. Pletan Y. Tonelli I. Tournoux A. Pezous N. (1998) Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatrica Scandinavica. 97(2):157-65

Van Moffaert M., De Wilde J., Veerecken A. et al. (1995). Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int. Clin. Psychopharmacol. 5: 441-446.